Company / R&D Expense
Veracyte, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$70.8M
FY2025
5-year range
$29.8M / $70.8M
FY2021-FY2025
Trend
+2.2%
vs FY2024
Sector context
#69 of 105
Health Care
What the data says
At $71M, Veracyte, Inc.'s r&d expense ranks #69 of 105 in the Health Care sector. R&D Expense has increased for 8 consecutive years, from $14M in FY2017 to $71M in FY2025.
Based on SEC 10-K filings.
$71M in FY2025 with a 5-year CAGR of +32.7%.
Improved from $57M to $71M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +20.4%
- 5-Year CAGR
- +32.7%
- 10-Year CAGR
- -
Sector benchmark
#69 of 105 in Health CareTop 66% of 105This company $70.8M Sector average $284.2M
▼
-75.1% below sector average
Key checks
Key Insights
- Veracyte, Inc.'s r&d expense has grown for 8 consecutive years.
- 5-year CAGR of +32.7%, indicating consistent growth.
- In FY2025, r&d expense increased 2.2% year-over-year.
- Ranks #69 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $70.8M | +2.2% |
| FY2024 | $69.3M | +20.9% |
| FY2023 | $57.3M | +41.1% |
| FY2022 | $40.6M | +36.1% |
| FY2021 | $29.8M | +73.5% |
| FY2020 | $17.2M | +15.8% |
| FY2019 | $14.9M | +0.2% |
| FY2018 | $14.8M | +6.8% |
| FY2017 | $13.9M | -9.4% |
| FY2016 | $15.3M | +19.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026